カテゴリ： GlobalData, アメリカ, 企業調査

Thermo Fisher Scientific Inc (TMO)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Thermo Fisher Scientific Inc (TMO) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7012
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：299
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories. It offers solutions for cellular analysis and biology, flow cytometry and synthetic biology. The company’s product portfolio includes technologies for mass spectrometry, electron microscopy, genetic sequencing, protein and molecular biology research. The company serves pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic labs, and government agencies; and environmental, industrial quality and process control sectors. It sells its products and services through direct sales force, e-commerce and third-party distributors in the Americas, Asia-Pacific and Europe. Thermo Fisher is headquartered in Waltham, Massachusetts, the US.

Thermo Fisher Scientific Inc (TMO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 13
Thermo Fisher Scientific Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 14
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 15
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 16
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 17
Thermo Fisher Scientific Inc, Medical Equipment, Deal Details 24
Asset Purchase 24
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 24
Visualization Sciences Completes Acquisition Of Amira 3D Visualization And Analysis Software From Visage Imaging For US$15 Million 25
Thermo Fisher Scientific Acquires Rights To Pre-eclampsia Biomarker From Nephromics 26
Venture Financing 27
Linkage Biosciences Raises US$2 Million In Series C Financing 27
IntegenX Raises US$49 Million In Venture Financing 28
Linkage Biosciences Raises US$1.5 Million In Venture Financing 29
KonTEM Raises Funds Through Venture Financing 30
Private Equity 31
GTCR Completes Acquisition of Cole-Parmer from Thermo Fisher for USD480 Million 31
Partnerships 32
Thermo Fisher Enters into Licensing Agreement with Siemens Healthineers 32
One Lambda Enters into Licensing Agreement with Transcriptome Sciences 33
Singulex Enters into Licensing agreement with Thermo Fisher Scientific 34
Thermo Fisher Scientific Enters into Licensing Agreement with Probiogen for GlymaxX Technology 35
Affymetrix Enters into Licensing Agreement with Peptide Groove 36
diaDexus Enters Into Licensing Agreement With Thermo Fisher Scientific 37
Life Technologies Enters Into Licensing Agreement With Quest Diagnostics For Development Of Molecular Tests 38
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 39
Medicyte Enters Into Licensing Agreement With Life Technologies For Next Generation Upcyte Cells 40
Life Technologies Enters Into Licensing And Research Agreement With Harvard For Stem Cell Assay 41
Affymetrix Enters Into Licensing Agreement With DNA Link To Develop Forensic And Other Diagnostic Tests 42
Thermo Fisher Scientific Enters Into Licensing Agreement With Fujirebio For Procalcitonin 43
Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 44
Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 45
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 46
Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 47
PharmaFluidics Enters into Partnership Agreement with Thermo Fisher 48
Thermo Fisher and Evosep Enter into Partnership 49
Spectrum Pharma Enters into Agreement with Thermo Fisher Scientific 50
Thermo Fisher and Leica Microsystems Enter into Partnership 51
Ortho Clinical Diagnostics Enters into Distribution and Co-Promotion Agreement with Thermo Fisher Scientific 52
BioDiscovery Enters into Agreement with Thermo Fisher Scientific 53
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 54
Genomics England, Inivata and Thermo Fisher Enter into Agreement 55
Seegene Enters into Agreement with Thermo Fisher Scientific 56
Thermo Fisher Scientific Enters into Agreement with Agios Pharma 57
Thermo Fisher Scientific Enters into Agreement with Institute of Medical Genetics and Pathology at University Hospital 58
Asuragen Enters into Agreement with Thermo Fisher Scientific 59
Invivoscribe Enters into Agreement with Thermo Fisher Scientific 60
Biocartis Group Enters into Distribution Agreement with Thermo Fisher Scientific 61
Thermo Fisher Scientific Enters into Agreement with Hamilton Storage Technologies 62
Thermo Fisher Scientific Enters into Co-Development Agreement with HEALTH BioMed 63
Thermo Fisher Scientific Enters into Co-Development Agreement with Cytonome 64
Strata Oncology Enters into Agreement with Thermo Fisher Scientific 65
Thermo Fisher Scientific Partners with University of Birmingham 66
HTG Molecular Diagnostics Enters into Agreement with Thermo Fisher Scientific 67
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 68
Thermo Fisher Scientific Enters into Co-Development Agreement with Children’s Hospital Los Angeles 69
Invivoscribe Enters into Co-Development Agreement with Thermo Fisher Scientific 70
Affymetrix Enters into Agreement with Reveal Biosciences 71
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 72
Agilent Technologies Enters into Agreement with Thermo Fisher Scientific 73
XRGenomics Enters into Research Agreement with Affymetrix 74
Affymetrix Enters into Distribution Agreement with Luminex 75
Instrumentation Laboratory Company Enters into Partnership with Thermo Fisher Scientific 76
Cytox Enters into Joint Development Partnership with Affymetrix 77
Atossa Genetics Enters into Distribution Agreement with Thermo Fisher 78
Thermo Fisher Scientific Enters into Distribution Agreement with Cynvenio Biosystems 79
Thermo Fisher Scientific Enters into Co-Development Agreement with Samsung Electronics 80
Ingen Expands Distribution Agreement with One Lambda 81
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 82
Lucigen Enters into Agreement with Thermo Fisher Scientific 83
Nuclea Biotech Enters into Co-Development Agreement with Thermo Fisher Scientific 84
Thermo Fisher Scientific Enters into Co-Development Agreement with Agricultural Research Service and Pennsylvania State University 85
Affymetrix Enters Into Integration Agreement With CollabRx 86
Copan Diagnostics Enters Into Distribution Agreement With Thermo Fisher For WASP 87
OraSure Technologies Enters Into Co-Development Agreement With Thermo Fisher 88
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 89
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 90
Thermo Fisher Scientific Enters Into Co-Marketing And Distribution Agreement With Quest Diagnostics 91
Life Technologies Enters Into Agreement With RainTree For Molecular Tumor Testing 92
Rheonix Enters Into Co-Development Agreement With Life Technologies For Molecular Testing Platform 93
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 94
Thermo Fisher Scientific And NLIPCC Enter Into R&D Agreement For Personalized Cancer Treatment 95
Atossa Genetics Enters Into Distribution Agreement With Fisher Healthcare For Breast Health Devices 96
Proteome Sciences Enters Into Co-Development Agreement With Thermo Fisher 97
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 98
Life Tech Enters Into Distribution Agreement With LGC Forensics For ParaDNA 99
Thermo Fisher Scientific Enters Into Research Agreement With University of Birmingham 100
Life Technologies And IMEGEN Enter Into Agreement To Develop DNA Test 101
Response Biomedical Enters Into Distribution Agreement With Fisher HealthCare 102
BioDesign Institute Enters Into Co-Development Agreement With Life Technologies 103
Affymetrix Enters Into Agreement With Hamilton Robotics To Develop Cytogenetics Assay 104
Boston Children’s Hospital Enters Into Joint Venture With Life Technologies To Form Claritas Genomics 105
Biocept Enters into Partnership with Life Technologies 106
Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 107
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 108
CollabRx Enters Into Co-Development Agreement With Life Technologies 109
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 110
Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 111
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 112
Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 113
Life Technologies and Southern African Treatment and Resistance Network Partner In Sequencing-Based Surveillance of Drug Resistance 114
Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 115
One Lambda Enters Into Co-Marketing Agreement With CellTrend 116
Affymetrix Enters Into Co-Development Agreement With Massachusetts General Hospital For New Oncology Biomarker Tests 117
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 118
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 119
Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 120
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 121
Iris International Enters Into Distribution Agreement With Fisher HealthCare 122
IRIS Sample Processing Enters Into Distribution Agreement With Fisher HealthCare 123
Thermo Fisher Scientific Enters Into Distribution Agreement With BellBrook Labs 124
Aushon BiosyStems Enters Into Distribution Agreement With Fisher Scientific 125
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 126
Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 127
Eppendorf Enters into Licensing Agreement with Life Tech and Alpha Labs 128
Life Technologies Enters Into Licensing Agreement With Novartis 129
Thermo Fisher Scientific Enter Into Licensing Agreement With Protein Metric For Proteomics Software 130
Equity Offering 131
Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 131
Affymetrix to Raise USD50 Million in Private Placement of Shares 133
Thermo Fisher Scientific Announces Private Placement Of Common Stock For US$500 Million 134
Thermo Fisher Completes Public Offering Of Shares For US$2.53 Billion 135
Patheon Completes Rights Offering Of Shares For US$30 Million 137
Affymetrix Files Registration Statement For Public Offering Of Securities For US$200 Million 138
Debt Offering 139
Thermo Fisher Scientific Prices Public Offering of Notes Due 2020 for USD694 Million 139
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 140
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 142
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 144
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 146
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 148
Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 150
Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 152
Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 154
Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 156
Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 158
Thermo Fisher Scientific Raises USD1 Billion in Public Offering of 3% Notes Due 2023 160
Thermo Fisher Scientific Raises USD350 Million in Public Offering of 3.65% Notes Due 2025 161
Thermo Fisher Scientific Raises USD450 Million in Public Offering of 2.150% Notes Due 2018 162
Thermo Fisher Scientific Raises USD457 Million in Public Offering of 1.5% Notes Due 2020 163
Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 165
Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 167
Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 169
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2044 For US$400 Million 171
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2024 For US$1 Billion 173
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2019 For US$900 Million 175
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2017 For US$900 Million 177
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2018 For US$500 Million 179
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2023 For US$800 Million 181
Affymetrix Completes Public Offering Of Notes Due 2019 For US$105 Million 183
Acquisition 185
Thermo Fisher Scientific Acquires IntegenX 185
One Lambda Acquires Linkage Biosciences 186
Thermo Fisher Scientific Acquires Finesse Solutions 187
Thermo Fisher Scientific Acquires FEI for USD4.2 Billion 188
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 190
Thermo Fisher Scientific Acquires Affymetrix for up to USD1.3 Billion 191
Thermo Fisher Scientific Acquires INEL 193
Thermo Fisher Scientific Acquires Advanced Scientifics for USD289 Million 194
FEI Company Acquires KonTEM, Developer of Innovative Phase Contrast System for TEM 195
EKF Diagnostics Acquires Separation Technology, Manufacturer Of In-Vitro Diagnostics Devices, From Thermo Fisher Scientific For US$4 Million 196
Thermo Fisher Scientific Completes Acquisition Of Life Technologies For US$13.6 Billion 197
FEI Company To Acquire nanoTechnology Systems 200
Life Technologies Acquires KDR Biotech, Distributor Of Reagents 201
Thermo Fisher Scientific Acquires picoSpin, Maker Of Miniature Nuclear Magnetic Resonance Spectrometer 202
Life Technologies Acquires Advanced Microscopy, Maker Of Microscopes 203
Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For US$925 Million 204
FEI Acquires Visualization Sciences, 3D Visualization Software Company, For US$55 Million 206
Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 207
Life Technologies Acquires Navigenics 208
Affymetrix Completes Acquisition Of eBioscience For US$315 Million 209
IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 211
Life Technologies Acquires Immuno-Magnetic Diagnostics Company, Matrix MicroScience 212
Thermo Fisher Scientific Inc – Key Competitors 213
Thermo Fisher Scientific Inc – Key Employees 214
Thermo Fisher Scientific Inc – Locations And Subsidiaries 216
Head Office 216
Other Locations & Subsidiaries 216
Joint Venture 220
Recent Developments 221
Strategy And Business Planning 221
Oct 02, 2018: Seoul St Mary s Hospital and Singapore General Hospital join Thermo Fisher Scientific s Next-Generation Sequencing Center of Excellence Program 221
Sep 20, 2018: Thermo Fisher scientific to launch global customer solution centers 222
Jun 04, 2018: Thermo Fisher Scientific Opens U.S. Precision Medicine Science Center 223
Mar 16, 2018: Thermo Fisher Scientific Announces Plans To Build State-Of-The-Art Pharma Services Facility In Rheinfelden 224
Dec 29, 2017: Thermo Fisher Scientific Completes Acquisition of Phenom-World 225
Financial Announcements 226
Jul 25, 2018: Thermo Fisher Scientific reports second quarter 2018 results 226
Apr 25, 2018: Thermo Fisher Scientific Reports First Quarter 2018 Results 228
Jan 31, 2018: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2017 Results 230
Oct 25, 2017: Thermo Fisher Scientific Reports Third Quarter 2017 Results 232
Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results 235
Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific 237
Apr 26, 2017: Thermo Fisher Scientific Reports First Quarter 2017 Results 238
Jan 31, 2017: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results 240
Corporate Communications 242
Jul 09, 2018: Thermo Fisher Offers to Donate DNA Analyzers to Support US-Mexico Border Family Reunions 242
Jun 24, 2018: Thermo Fisher Scientific Donates Rapid DNA Analysis Technology to Help Reunite Families Recently Separated at Border 243
Jan 22, 2018: Secured loan facility agreement with Thermo Fisher 244
Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific 245
Mar 01, 2017: Thermo Fisher Scientific Elects New Director to Board 246
Legal and Regulatory 247
Mar 27, 2018: New Salmonella Multiplex PCR Solution for Simultaneous Detection of Three Salmonella Targets in One Rapid Test is Now Certified by AFNOR 247
Jan 23, 2017: ISO 17025 Accreditation for Microbiology Manufacturing Site Offers Increased Confidence to Microbiology Testing Laboratories 248
Product News 249
Sep 24, 2018: New Single Quadrupole Mass Spectrometry Technology Designed for Chromatographers Performing LC-MS Routine Analysis 249
Aug 06, 2018: Thermo Fisher Scientific Showcases New Electron Microscopy and Microanalysis Solutions at M&M 2018 250
Jul 31, 2018: New triple quadrupole mass spectrometer offers robust and fast analysis with LC-MS/MS for clinical research laboratories 252
Jul 02, 2018: Latin American Structural Biologists Gain Access to Cryo-EM Capabilities 253
Jun 28, 2018: Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio 254
Jun 25, 2018: New Twin-screw Granulator Helps Maximize Throughput in Continuous Drug Manufacturing 255
Jun 18, 2018: Thermo Fisher Scientific Launches Ion AmpliSeq HD Technology 256
Jun 04, 2018: New Ultra-High Mass Range Mass Spectrometer Provides Solution for Analysis of Proteins and Protein Complexes 257
Jun 04, 2018: Thermo Fisher Scientific showcases newest products at ASMS 2018 258
Apr 26, 2018: Thermo Scientific Explorer 4 Additive Scanning Electron Microscope Delivers First Dedicated Solution for 3D Printing Process Control 260
Apr 16, 2018: Thermo Fisher Scientific Launches Oncomine Childhood Cancer Research Assay and Establishes International Childhood Oncology Network 261
Apr 12, 2018: Thermo Fisher Scientific to Showcase Clinical Research Advances in Immuno-Oncology at AACR 262
Apr 10, 2018: Thermo Fisher launches five new products at Analytica 2018 263
Apr 10, 2018: Thermo Fisher Scientific Highlights Digital Science Innovations at Analytica 2018 264
Feb 27, 2018: Thermo Fisher Scientific Innovations Offer Greater Connectivity and Ease of Use 266
Feb 05, 2018: Thermo Fisher Scientific Launches Axiom Microbiome Array for Research 267
Jan 08, 2018: Thermo Fisher Scientific Expands Oncomine Portfolio for Liquid Biopsy and Immuno-oncology Clinical Research 268
Jan 08, 2018: Thermo Fisher Scientific Introduces Ion GeneStudio S5 Series, A Line of Highly Versatile Next Generation Sequencers 270
Dec 07, 2017: New Myeloid Research Assay Combines Simultaneous DNA and RNA Analysis of Most Relevant Hematologic Cancer Driver Genes 271
Nov 27, 2017: Expanded Genome Editing Tool Kit Supports Every Step in Researchers’ Workflow 272
Nov 04, 2017: Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping 273
Oct 17, 2017: Thermo Fisher Scientific Customers to Showcase Innovations in Precision Genomics Research for Inherited Disease and Reproductive Health at ASHG 274
Sep 26, 2017: Thermo Fisher Scientific Continues to Expand Plasmid DNA Purification Portfolio of Low-Endotoxin Plasmid DNA Isolation Kits 275
Sep 05, 2017: New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings 276
Aug 31, 2017: Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe 277
Aug 07, 2017: Thermo Fisher Scientific Showcases Innovations in Electron Microscopy and Spectroscopy at M&M 2017 278
Jul 31, 2017: Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017 279
Jun 29, 2017: New FDA-Cleared Microbroth Dilution Susceptibility Testing Plate Expands Patient Treatment Options for Gram Negative Infections 280
Jun 05, 2017: Thermo Fisher Scientific and BIOCRATES Life Sciences Launch Industry’s First Kit for Comprehensive Metabolome Analysis 281
Jun 02, 2017: Newly Redesigned Panels Align with Most Recent Published Evidence to Drive Cancer Research 282
May 24, 2017: New On-Demand Targeted Next-Generation Sequencing Panels for Inherited Disease Research Deliver User Customization Without High Upfront Cost 283
May 22, 2017: Thermo Fisher Scientific Introduces Latest in Capillary Electrophoresis Technology with new Applied Biosystems SeqStudio Genetic Analyzer 284
Mar 21, 2017: New Comprehensive Carrier Screening Research Assay Features Richest Pan-Ethnic Panel for Detection of Multiple Genetic Variations in Inherited Disease 285
Mar 20, 2017: Thermo Fisher Scientific Showcases Newest Bioprocessing Technologies at INTERPHEX 286
Other Significant Developments 287
Oct 02, 2018: Seoul St. Mary”s Hospital and Singapore General Hospital join Thermo Fisher Scientific”s next-generation sequencing Center of Excellence Program 287
Jul 10, 2018: Thermo Fisher Scientific to publish antibody data 288
May 18, 2018: Bard1 Enters agreement to Develop a Research-Use-Only Auto antibody Test System Using Procartaplex Technology 289
Mar 28, 2018: Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration 290
Mar 21, 2018: Thermo Fisher says UK job cuts not Brexit-related 291
Feb 21, 2018: Millions of U.S. Allergy Sufferers Now Have Access to Advanced Diagnostic Tests 292
Feb 13, 2018: OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas Tests 293
Jan 31, 2018: Thermo Fisher Scientific Uses Tax Reform Benefit to Make Additional Investments in Colleagues, Customers and Communities 294
Jan 08, 2018: Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology 295
Sep 07, 2017: Institute of Pathology Heidelberg Joins Thermo Fisher Scientific Center of Excellence Program to Drive Oncology Companion Diagnostic Development in Europe 296
Jun 12, 2017: Allergen Sensitization Testing Breakthrough Marks 50th Anniversary 297
May 04, 2017: New Licensing Program Facilitates Adoption of Tandem Mass Tag Technology 298
Appendix 299
Methodology 299
About GlobalData 299
Contact Us 299
Disclaimer 299

List of Tables
Thermo Fisher Scientific Inc, Medical Equipment, Key Facts, 2017 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 13
Thermo Fisher Scientific Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 14
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 15
Thermo Fisher Scientific Inc, Deals By Market, 2012 to YTD 2018 16
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 17
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 24
Visualization Sciences Completes Acquisition Of Amira 3D Visualization And Analysis Software From Visage Imaging For US$15 Million 25
Thermo Fisher Scientific Acquires Rights To Pre-eclampsia Biomarker From Nephromics 26
Linkage Biosciences Raises US$2 Million In Series C Financing 27
IntegenX Raises US$49 Million In Venture Financing 28
Linkage Biosciences Raises US$1.5 Million In Venture Financing 29
KonTEM Raises Funds Through Venture Financing 30
GTCR Completes Acquisition of Cole-Parmer from Thermo Fisher for USD480 Million 31
Thermo Fisher Enters into Licensing Agreement with Siemens Healthineers 32
One Lambda Enters into Licensing Agreement with Transcriptome Sciences 33
Singulex Enters into Licensing agreement with Thermo Fisher Scientific 34
Thermo Fisher Scientific Enters into Licensing Agreement with Probiogen for GlymaxX Technology 35
Affymetrix Enters into Licensing Agreement with Peptide Groove 36
diaDexus Enters Into Licensing Agreement With Thermo Fisher Scientific 37
Life Technologies Enters Into Licensing Agreement With Quest Diagnostics For Development Of Molecular Tests 38
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 39
Medicyte Enters Into Licensing Agreement With Life Technologies For Next Generation Upcyte Cells 40
Life Technologies Enters Into Licensing And Research Agreement With Harvard For Stem Cell Assay 41
Affymetrix Enters Into Licensing Agreement With DNA Link To Develop Forensic And Other Diagnostic Tests 42
Thermo Fisher Scientific Enters Into Licensing Agreement With Fujirebio For Procalcitonin 43
Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 44
Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 45
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 46
Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 47
PharmaFluidics Enters into Partnership Agreement with Thermo Fisher 48
Thermo Fisher and Evosep Enter into Partnership 49
Spectrum Pharma Enters into Agreement with Thermo Fisher Scientific 50
Thermo Fisher and Leica Microsystems Enter into Partnership 51
Ortho Clinical Diagnostics Enters into Distribution and Co-Promotion Agreement with Thermo Fisher Scientific 52
BioDiscovery Enters into Agreement with Thermo Fisher Scientific 53
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 54
Genomics England, Inivata and Thermo Fisher Enter into Agreement 55
Seegene Enters into Agreement with Thermo Fisher Scientific 56
Thermo Fisher Scientific Enters into Agreement with Agios Pharma 57
Thermo Fisher Scientific Enters into Agreement with Institute of Medical Genetics and Pathology at University Hospital 58
Asuragen Enters into Agreement with Thermo Fisher Scientific 59
Invivoscribe Enters into Agreement with Thermo Fisher Scientific 60
Biocartis Group Enters into Distribution Agreement with Thermo Fisher Scientific 61
Thermo Fisher Scientific Enters into Agreement with Hamilton Storage Technologies 62
Thermo Fisher Scientific Enters into Co-Development Agreement with HEALTH BioMed 63
Thermo Fisher Scientific Enters into Co-Development Agreement with Cytonome 64
Strata Oncology Enters into Agreement with Thermo Fisher Scientific 65
Thermo Fisher Scientific Partners with University of Birmingham 66
HTG Molecular Diagnostics Enters into Agreement with Thermo Fisher Scientific 67
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 68
Thermo Fisher Scientific Enters into Co-Development Agreement with Children’s Hospital Los Angeles 69
Invivoscribe Enters into Co-Development Agreement with Thermo Fisher Scientific 70
Affymetrix Enters into Agreement with Reveal Biosciences 71
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 72
Agilent Technologies Enters into Agreement with Thermo Fisher Scientific 73
XRGenomics Enters into Research Agreement with Affymetrix 74
Affymetrix Enters into Distribution Agreement with Luminex 75
Instrumentation Laboratory Company Enters into Partnership with Thermo Fisher Scientific 76
Cytox Enters into Joint Development Partnership with Affymetrix 77
Atossa Genetics Enters into Distribution Agreement with Thermo Fisher 78
Thermo Fisher Scientific Enters into Distribution Agreement with Cynvenio Biosystems 79
Thermo Fisher Scientific Enters into Co-Development Agreement with Samsung Electronics 80
Ingen Expands Distribution Agreement with One Lambda 81
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 82
Lucigen Enters into Agreement with Thermo Fisher Scientific 83
Nuclea Biotech Enters into Co-Development Agreement with Thermo Fisher Scientific 84
Thermo Fisher Scientific Enters into Co-Development Agreement with Agricultural Research Service and Pennsylvania State University 85
Affymetrix Enters Into Integration Agreement With CollabRx 86
Copan Diagnostics Enters Into Distribution Agreement With Thermo Fisher For WASP 87
OraSure Technologies Enters Into Co-Development Agreement With Thermo Fisher 88
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 89
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 90
Thermo Fisher Scientific Enters Into Co-Marketing And Distribution Agreement With Quest Diagnostics 91
Life Technologies Enters Into Agreement With RainTree For Molecular Tumor Testing 92
Rheonix Enters Into Co-Development Agreement With Life Technologies For Molecular Testing Platform 93
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 94
Thermo Fisher Scientific And NLIPCC Enter Into R&D Agreement For Personalized Cancer Treatment 95
Atossa Genetics Enters Into Distribution Agreement With Fisher Healthcare For Breast Health Devices 96
Proteome Sciences Enters Into Co-Development Agreement With Thermo Fisher 97
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 98
Life Tech Enters Into Distribution Agreement With LGC Forensics For ParaDNA 99
Thermo Fisher Scientific Enters Into Research Agreement With University of Birmingham 100
Life Technologies And IMEGEN Enter Into Agreement To Develop DNA Test 101
Response Biomedical Enters Into Distribution Agreement With Fisher HealthCare 102
BioDesign Institute Enters Into Co-Development Agreement With Life Technologies 103
Affymetrix Enters Into Agreement With Hamilton Robotics To Develop Cytogenetics Assay 104
Boston Children's Hospital Enters Into Joint Venture With Life Technologies To Form Claritas Genomics 105
Biocept Enters into Partnership with Life Technologies 106
Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 107
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 108
CollabRx Enters Into Co-Development Agreement With Life Technologies 109
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 110
Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 111
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 112
Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 113
Life Technologies and Southern African Treatment and Resistance Network Partner In Sequencing-Based Surveillance of Drug Resistance 114
Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 115
One Lambda Enters Into Co-Marketing Agreement With CellTrend 116
Affymetrix Enters Into Co-Development Agreement With Massachusetts General Hospital For New Oncology Biomarker Tests 117
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 118
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 119
Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 120
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 121
Iris International Enters Into Distribution Agreement With Fisher HealthCare 122
IRIS Sample Processing Enters Into Distribution Agreement With Fisher HealthCare 123
Thermo Fisher Scientific Enters Into Distribution Agreement With BellBrook Labs 124
Aushon BiosyStems Enters Into Distribution Agreement With Fisher Scientific 125
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 126
Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 127
Eppendorf Enters into Licensing Agreement with Life Tech and Alpha Labs 128
Life Technologies Enters Into Licensing Agreement With Novartis 129
Thermo Fisher Scientific Enter Into Licensing Agreement With Protein Metric For Proteomics Software 130
Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 131
Affymetrix to Raise USD50 Million in Private Placement of Shares 133
Thermo Fisher Scientific Announces Private Placement Of Common Stock For US$500 Million 134
Thermo Fisher Completes Public Offering Of Shares For US$2.53 Billion 135
Patheon Completes Rights Offering Of Shares For US$30 Million 137
Affymetrix Files Registration Statement For Public Offering Of Securities For US$200 Million 138
Thermo Fisher Scientific Prices Public Offering of Notes Due 2020 for USD694 Million 139
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 140
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 142
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 144
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 146
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 148
Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 150
Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 152
Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 154
Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 156
Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 158
Thermo Fisher Scientific Raises USD1 Billion in Public Offering of 3% Notes Due 2023 160
Thermo Fisher Scientific Raises USD350 Million in Public Offering of 3.65% Notes Due 2025 161
Thermo Fisher Scientific Raises USD450 Million in Public Offering of 2.150% Notes Due 2018 162
Thermo Fisher Scientific Raises USD457 Million in Public Offering of 1.5% Notes Due 2020 163
Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 165
Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 167
Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 169
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2044 For US$400 Million 171
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2024 For US$1 Billion 173
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2019 For US$900 Million 175
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2017 For US$900 Million 177
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2018 For US$500 Million 179
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2023 For US$800 Million 181
Affymetrix Completes Public Offering Of Notes Due 2019 For US$105 Million 183
Thermo Fisher Scientific Acquires IntegenX 185
One Lambda Acquires Linkage Biosciences 186
Thermo Fisher Scientific Acquires Finesse Solutions 187
Thermo Fisher Scientific Acquires FEI for USD4.2 Billion 188
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 190
Thermo Fisher Scientific Acquires Affymetrix for up to USD1.3 Billion 191
Thermo Fisher Scientific Acquires INEL 193
Thermo Fisher Scientific Acquires Advanced Scientifics for USD289 Million 194
FEI Company Acquires KonTEM, Developer of Innovative Phase Contrast System for TEM 195
EKF Diagnostics Acquires Separation Technology, Manufacturer Of In-Vitro Diagnostics Devices, From Thermo Fisher Scientific For US$4 Million 196
Thermo Fisher Scientific Completes Acquisition Of Life Technologies For US$13.6 Billion 197
FEI Company To Acquire nanoTechnology Systems 200
Life Technologies Acquires KDR Biotech, Distributor Of Reagents 201
Thermo Fisher Scientific Acquires picoSpin, Maker Of Miniature Nuclear Magnetic Resonance Spectrometer 202
Life Technologies Acquires Advanced Microscopy, Maker Of Microscopes 203
Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For US$925 Million 204
FEI Acquires Visualization Sciences, 3D Visualization Software Company, For US$55 Million 206
Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 207
Life Technologies Acquires Navigenics 208
Affymetrix Completes Acquisition Of eBioscience For US$315 Million 209
IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 211
Life Technologies Acquires Immuno-Magnetic Diagnostics Company, Matrix MicroScience 212
Thermo Fisher Scientific Inc, Key Competitors 213
Thermo Fisher Scientific Inc, Key Employees 214
Thermo Fisher Scientific Inc, Subsidiaries 216
Thermo Fisher Scientific Inc, Joint Venture 220

List of Figures
Thermo Fisher Scientific Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 13
Thermo Fisher Scientific Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 14
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 15
Thermo Fisher Scientific Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 16

★海外企業調査レポート[Thermo Fisher Scientific Inc (TMO)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AFC Energy plc (AFC)：企業の財務・戦略的SWOT分析
    Summary AFC Energy Plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. AFC Energy power generation technology is used in the industrial markets and produces heat, water, and electricity. The company provides its electricity for industrial a …
  • Tootsie Roll Industries, Inc.：企業の戦略・SWOT・財務情報
    Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Forrester Research, Inc.：企業の戦略・SWOT・財務分析
    Forrester Research, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forrester Research, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ImpediMed Ltd (IPD)：企業の財務・戦略的SWOT分析
    ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • ABC arbitrage SA (ABCA)：企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Omega Pharma NV-製薬・医療分野：企業M&A・提携分析
    Summary Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company's product portfolio includes cough and cold product …
  • The Cheesecake Factory Incorporated：企業の戦略・SWOT・財務分析
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Suzuken Co Ltd (9987)：企業の財務・戦略的SWOT分析
    Suzuken Co Ltd (9987) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Msc Industrial Direct Co., Inc.
    Msc Industrial Direct Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Msc Industrial Direct Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • KVK-Tech Inc-製薬・医療分野：企業M&A・提携分析
    Summary KVK-Tech Inc (KVK-Tech) is a manufacturer and marketer generic drugs. The company's product portfolio includes benzphetamine HCL, betaxolol, chlorphen-12, cyclobenzaprine HCL, diethylpropion HCL, hydroxyzine HCL, indomethacin extended release, phendimetrazine tartrate, phentermine HCL, prome …
  • Microsoft Corporation：企業のM&A・事業提携・投資動向
    Microsoft Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Microsoft Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Homology Medicines, Inc. (FIXX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Homology Medicines, Inc. (Homology Medicines) is a pre-clinical stage biopharmaceutical company engaged in translating gene editing and gene therapy into novel treatment for patients suffering from rare genetic diseases. It offers HMI-102 product, which is in clinical stage for the treatment …
  • Heidelberg Pharma AG (WL6)：企業の財務・戦略的SWOT分析
    Heidelberg Pharma AG (WL6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Exterran Corp (EXTN)：企業の財務・戦略的SWOT分析
    Exterran Corp (EXTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Calix, Inc. (CALX)：企業の財務・戦略的SWOT分析
    Calix, Inc. (CALX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sykes Enterprises, Incorporated：企業の戦略・SWOT・財務分析
    Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Herti AD：企業の戦略・SWOT・財務情報
    Herti AD - Strategy, SWOT and Corporate Finance Report Summary Herti AD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Mateon Therapeutics Inc (MATN)：企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • Ok Tedi Mining Ltd：企業の戦略・SWOT・財務情報
    Ok Tedi Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Ok Tedi Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Biotec Pharmacon ASA (BIOTEC)：企業の財務・戦略的SWOT分析
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆